Novavax is on thin ice, and the latest update isn’t exactly encouraging
STAT
FEBRUARY 1, 2024
On 2024 guidance, Merck said it expects sales in the range of $62.7-$64.2 In 2024, as in 2023, the industry’s fate seems inextricable from interest rates. Novavax won’t disclose its revenue until later this month, but its latest communications don’t exactly inspire confidence. Just some food for thought.
107 
Let's personalize your content